See more : VPN Technologies Inc. (DVPNF) Income Statement Analysis – Financial Results
Complete financial analysis of Biomerica, Inc. (BMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biomerica, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Acsion Limited (ACS.JO) Income Statement Analysis – Financial Results
- CKD Corporation (6407.T) Income Statement Analysis – Financial Results
- Global Star Acquisition, Inc. (GLSTW) Income Statement Analysis – Financial Results
- Acutus Medical, Inc. (AFIB) Income Statement Analysis – Financial Results
- Tetragon Financial Group Limited (TFG.L) Income Statement Analysis – Financial Results
Biomerica, Inc. (BMRA)
About Biomerica, Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.42M | 5.34M | 18.87M | 7.20M | 6.69M | 5.20M | 5.56M | 5.79M | 5.14M | 4.96M | 5.12M | 6.47M | 6.08M | 4.90M | 5.08M | 4.93M | 4.93M | 5.75M | 7.18M | 9.27M | 9.17M | 9.06M | 8.60M | 8.94M | 8.03M | 8.70M | 9.40M | 9.20M | 9.50M | 9.20M | 8.30M | 8.00M | 7.80M | 10.40M | 8.20M | 1.20M | 1.40M | 1.90M | 1.70M |
| Cost of Revenue | 4.80M | 4.89M | 15.89M | 6.70M | 4.91M | 3.91M | 3.81M | 3.77M | 3.62M | 3.42M | 3.45M | 4.05M | 3.78M | 3.37M | 3.51M | 2.96M | 2.79M | 3.50M | 4.78M | 6.19M | 6.25M | 6.16M | 6.06M | 6.13M | 5.40M | 5.10M | 5.30M | 5.20M | 5.10M | 4.80M | 4.30M | 4.80M | 4.80M | 6.70M | 4.00M | 800.00K | 1.00M | 800.00K | 1.20M |
| Gross Profit | 611.00K | 446.00K | 2.98M | 496.98K | 1.78M | 1.29M | 1.75M | 2.02M | 1.52M | 1.54M | 1.67M | 2.43M | 2.30M | 1.53M | 1.56M | 1.97M | 2.14M | 2.25M | 2.41M | 3.09M | 2.92M | 2.90M | 2.54M | 2.81M | 2.63M | 3.60M | 4.10M | 4.00M | 4.40M | 4.40M | 4.00M | 3.20M | 3.00M | 3.70M | 4.20M | 400.00K | 400.00K | 1.10M | 500.00K |
| Gross Profit Ratio | 11.28% | 8.35% | 15.78% | 6.90% | 26.62% | 24.84% | 31.53% | 34.91% | 29.65% | 31.07% | 32.60% | 37.51% | 37.78% | 31.14% | 30.75% | 39.92% | 43.35% | 39.07% | 33.48% | 33.27% | 31.81% | 31.99% | 29.49% | 31.43% | 32.75% | 41.38% | 43.62% | 43.48% | 46.32% | 47.83% | 48.19% | 40.00% | 38.46% | 35.58% | 51.22% | 33.33% | 28.57% | 57.89% | 29.41% |
| Research & Development | 1.49M | 1.58M | 1.81M | 2.41M | 1.91M | 1.68M | 1.40M | 1.13M | 780.33K | 733.64K | 589.87K | 459.09K | 347.13K | 420.57K | 455.17K | 278.31K | 259.09K | 256.10K | 239.00K | 274.29K | 273.98K | 262.84K | 159.76K | 322.12K | 898.12K | 500.00K | 600.00K | 300.00K | 300.00K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.61K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.49M | 6.09M | 5.70M | 4.61M | 2.27M | 2.03M | 1.84M | 1.85M | 1.57M | 1.48M | 1.53M | 1.45M | 1.45M | 1.24M | 1.47M | 1.44M | 1.37M | 1.47M | 2.26M | 3.05M | 2.96M | 2.85M | 2.84M | 3.17M | 5.70M | 3.10M | 3.10M | 2.90M | 3.10M | 3.30M | 3.40M | 3.00M | 3.60M | 4.80M | 3.70M | 1.20M | 1.90M | 2.30M | 2.40M |
| Other Expenses | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.01K | 2.26K | 3.13K | 50.00 | 0.00 | 290.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.98M | 7.67M | 7.51M | 7.02M | 4.18M | 3.70M | 3.24M | 2.98M | 2.35M | 2.21M | 2.12M | 1.91M | 1.79M | 1.66M | 1.93M | 1.72M | 1.63M | 1.72M | 2.50M | 3.32M | 3.23M | 3.11M | 3.00M | 3.49M | 6.82M | 3.90M | 3.90M | 3.40M | 3.70M | 4.00M | 3.80M | 3.50M | 4.40M | 5.60M | 4.20M | 1.30M | 2.00M | 2.40M | 2.60M |
| Cost & Expenses | 11.78M | 12.56M | 23.41M | 13.72M | 9.10M | 7.61M | 7.05M | 6.75M | 5.97M | 5.63M | 5.57M | 5.96M | 5.58M | 5.03M | 5.44M | 4.69M | 4.42M | 5.23M | 7.28M | 9.51M | 9.48M | 9.27M | 9.06M | 9.62M | 12.22M | 9.00M | 9.20M | 8.60M | 8.80M | 8.80M | 8.10M | 8.30M | 9.20M | 12.30M | 8.20M | 2.10M | 3.00M | 3.20M | 3.80M |
| Interest Income | 431.00K | 133.00K | 26.64K | 66.86K | 71.19K | 44.01K | 47.76K | 46.35K | 24.12K | 21.91K | 17.18K | 10.71K | 8.35K | 7.37K | 14.71K | 29.87K | 33.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 26.64K | 367.00 | 9.00 | 47.00 | 37.00 | 282.00 | 167.00 | 0.00 | 142.00 | 302.00 | 1.59K | 5.83K | 12.32K | 27.52K | 49.54K | 35.05K | 0.00 | 0.00 | 0.00 | 0.00 | 40.37K | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 374.00K | 351.00K | 594.82K | 375.86K | 398.63K | 162.91K | 186.60K | 219.22K | 232.42K | 253.28K | 207.03K | 216.71K | 180.12K | 147.81K | 114.01K | 88.65K | 65.83K | 56.74K | 122.05K | 159.32K | 144.16K | 116.55K | 192.42K | 208.99K | 222.33K | 300.00K | 200.00K | 200.00K | 300.00K | 400.00K | 400.00K | 500.00K | 800.00K | 800.00K | 500.00K | 100.00K | 100.00K | 100.00K | 200.00K |
| EBITDA | -5.99M | -6.74M | -3.94M | -7.06M | -2.27M | -2.21M | -1.25M | -689.34K | -563.57K | -393.15K | -219.25K | 741.48K | 795.16K | 313.09K | -218.12K | 383.36K | 1.72M | 537.49K | 24.96K | -75.45K | -171.98K | -93.34K | -273.00K | -408.86K | -3.97M | 0.00 | 400.00K | 800.00K | 1.00M | 800.00K | 600.00K | 200.00K | -600.00K | -1.10M | 800.00K | -800.00K | -1.50M | -1.20M | -1.90M |
| EBITDA Ratio | -110.67% | -128.71% | -20.73% | -84.45% | -28.88% | -42.42% | -22.42% | -11.90% | -10.96% | -7.92% | -4.28% | 11.45% | 11.27% | 6.39% | -4.65% | 7.42% | -11.66% | 9.35% | -0.29% | -1.20% | -2.74% | -1.80% | -2.80% | -5.84% | -50.86% | -3.45% | 2.13% | 7.61% | 10.53% | 8.70% | 7.23% | 1.25% | -8.97% | -10.58% | 9.76% | -75.00% | -178.57% | -57.89% | -105.88% |
| Operating Income | -6.37M | -7.22M | -4.53M | -6.52M | -2.40M | -2.41M | -1.48M | -954.63K | -826.95K | -670.60K | -446.59K | 514.01K | 505.00K | -132.26K | -364.52K | 247.66K | 509.49K | 520.79K | -97.09K | -234.76K | -316.14K | -209.88K | -465.42K | -683.58K | -4.19M | -300.00K | 200.00K | 600.00K | 700.00K | 400.00K | 200.00K | -300.00K | -1.40M | -1.90M | 300.00K | -900.00K | -1.60M | -1.30M | -2.10M |
| Operating Income Ratio | -117.58% | -135.29% | -24.03% | -90.60% | -35.90% | -46.39% | -26.63% | -16.48% | -16.09% | -13.51% | -8.72% | 7.94% | 8.30% | -2.70% | -7.18% | 5.02% | 10.34% | 9.06% | -1.35% | -2.53% | -3.45% | -2.32% | -5.41% | -7.65% | -52.16% | -3.45% | 2.13% | 6.52% | 7.37% | 4.35% | 2.41% | -3.75% | -17.95% | -18.27% | 3.66% | -75.00% | -114.29% | -68.42% | -123.53% |
| Total Other Income/Expenses | 431.00K | 134.00K | 26.64K | 66.50K | 71.18K | 43.97K | 47.73K | 46.07K | 30.97K | 24.16K | 20.17K | 10.46K | 108.45K | 291.71K | 20.07K | 19.52K | 1.13M | 4.99K | 785.00 | 215.24K | 18.91K | -11.77K | -99.19K | 103.21K | 301.56K | 300.00K | -200.00K | 100.00K | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K | 900.00K | -300.00K | 100.00K | 1.00M | -100.00K | -100.00K |
| Income Before Tax | -5.94M | -7.09M | -4.51M | -6.46M | -2.33M | -2.37M | -1.43M | -908.56K | -795.99K | -646.43K | -426.42K | 524.46K | 613.45K | 159.45K | -344.46K | 267.18K | 1.64M | 525.78K | 155.37K | -19.53K | -297.23K | -221.65K | -564.61K | -576.49K | -3.89M | 0.00 | 400.00K | 700.00K | 0.00 | 0.00 | 300.00K | -200.00K | -1.30M | -1.00M | 0.00 | -800.00K | -600.00K | -1.40M | -2.20M |
| Income Before Tax Ratio | -109.62% | -132.78% | -23.88% | -89.68% | -34.84% | -45.55% | -25.77% | -15.69% | -15.49% | -13.03% | -8.33% | 8.10% | 10.09% | 3.25% | -6.79% | 5.41% | 33.35% | 9.15% | 2.16% | -0.21% | -3.24% | -2.45% | -6.57% | -6.45% | -48.40% | 0.00% | 4.26% | 7.61% | 0.00% | 0.00% | 3.61% | -2.50% | -16.67% | -9.62% | 0.00% | -66.67% | -42.86% | -73.68% | -129.41% |
| Income Tax Expense | 42.00K | 51.00K | 23.72K | 13.06K | 7.39K | 24.24K | 31.80K | 46.64K | 703.80K | -315.02K | -210.76K | -12.49K | 65.01K | 2.00K | -13.00K | -87.00K | -67.00K | 16.77K | 1.60K | 1.94K | 1.82K | 2.22K | 2.06K | 2.40K | 2.40K | -200.00K | 100.00K | 200.00K | 300.00K | 300.00K | 300.00K | 100.00K | -500.00K | 200.00K | 600.00K | 0.00 | -1.20M | 0.00 | -200.00K |
| Net Income | -5.98M | -7.14M | -4.53M | -6.47M | -2.34M | -2.39M | -1.47M | -908.56K | -1.50M | -331.41K | -215.66K | 536.96K | 548.44K | 157.45K | -331.46K | 354.18K | 1.71M | 536.88K | 230.27K | 162.26K | -223.20K | -223.87K | -420.74K | -2.67M | -3.89M | -100.00K | 100.00K | 400.00K | 400.00K | 100.00K | 0.00 | -400.00K | -900.00K | -1.20M | -600.00K | -900.00K | -400.00K | -1.30M | -1.90M |
| Net Income Ratio | -110.40% | -133.73% | -24.01% | -89.86% | -34.95% | -46.01% | -26.34% | -15.69% | -29.18% | -6.68% | -4.21% | 8.30% | 9.02% | 3.21% | -6.53% | 7.18% | 34.71% | 9.34% | 3.20% | 1.75% | -2.43% | -2.47% | -4.89% | -29.89% | -48.43% | -1.15% | 1.06% | 4.35% | 4.21% | 1.09% | 0.00% | -5.00% | -11.54% | -11.54% | -7.32% | -75.00% | -28.57% | -68.42% | -111.76% |
| EPS | -0.36 | -0.50 | -0.36 | -0.54 | -0.23 | -0.26 | -0.17 | -0.11 | -0.20 | -0.04 | -0.03 | 0.08 | 0.08 | 0.02 | -0.05 | 0.05 | 0.28 | 0.09 | 0.04 | 0.03 | -0.04 | -0.04 | -0.08 | -0.56 | -0.86 | -0.03 | 0.04 | 0.12 | 0.12 | 0.03 | 0.02 | -0.14 | -0.30 | -0.40 | -0.18 | -0.30 | -0.14 | -0.44 | -0.66 |
| EPS Diluted | -0.36 | -0.50 | -0.36 | -0.54 | -0.23 | -0.26 | -0.17 | -0.11 | -0.20 | -0.04 | -0.03 | 0.07 | 0.08 | 0.02 | -0.05 | 0.05 | 0.25 | 0.08 | 0.03 | 0.03 | -0.04 | -0.04 | -0.08 | -0.56 | -0.86 | -0.03 | 0.03 | 0.10 | 0.12 | 0.03 | 0.02 | -0.14 | -0.30 | -0.40 | -0.18 | -0.30 | -0.14 | -0.44 | -0.66 |
| Weighted Avg Shares Out | 16.82M | 14.15M | 12.67M | 11.93M | 10.17M | 9.21M | 8.57M | 8.26M | 7.50M | 7.55M | 7.19M | 7.02M | 6.89M | 6.67M | 6.65M | 6.62M | 6.13M | 5.93M | 5.76M | 5.75M | 5.74M | 5.30M | 5.10M | 4.81M | 4.54M | 4.00M | 4.00M | 3.86M | 3.59M | 3.33M | 3.33M | 2.86M | 3.00M | 3.00M | 3.33M | 3.00M | 2.86M | 2.95M | 2.88M |
| Weighted Avg Shares Out (Dil) | 16.82M | 14.15M | 12.67M | 11.93M | 10.17M | 9.21M | 8.57M | 8.33M | 7.63M | 7.55M | 7.37M | 7.45M | 7.11M | 6.70M | 6.65M | 7.01M | 6.98M | 6.51M | 6.22M | 6.62M | 5.74M | 5.30M | 5.10M | 4.81M | 4.54M | 4.00M | 4.00M | 3.87M | 3.59M | 3.33M | 3.33M | 2.86M | 3.00M | 3.00M | 3.33M | 3.00M | 2.86M | 2.95M | 2.88M |
Short Squeeze Stocks: BMRA, PROG and 3 Other Stocks Experts Think Are Ready to Pop
According to Fintel, here are five short squeeze stocks that are among the most likely to see a squeeze attempt moving forward. The post Short Squeeze Stocks: BMRA, PROG and 3 Other Stocks Experts Think Are Ready to Pop appeared...
5 Short Squeeze Candidates To Watch: Aterian, Marin On List Again, Plus 3 New Small-Cap Medical Plays
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) and AMC Entertainment Holdings Inc (NYSE: AMC), two stocks that attracted strong interest and saw shares spike. A short...
BMRA Stock Price: Why It Increased 38%
The stock price of Biomerica, Inc. (NASDAQ: BMRA) increased by 38% in the previous trading session. This is why it happened.
BMRA Stock: The Big Walmart Deal That Has Biomerica Investors Smiling Today
Biomerica (BMRA) stock is surging higher on Friday thanks to a new deal with Walmart (WMT) concerning its EZ Detect product. The post BMRA Stock: The Big Walmart Deal That Has Biomerica Investors Smiling Today appeared first on InvestorPlace.
Walmart Now Selling Biomerica's EZ Detect™ Colorectal Screening Test
IRVINE, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that it has entered into a General Merchandise Supplier Agreement with Walmart for the sale of the Company's EZ Detect™ colorectal disease screening test...
Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022
Biomerica recently reported its fiscal 2021 Q4 results highlighted by key product updates supporting a positive long-term outlook.
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
IRVINE, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it expects final patient enrollment in its endpoint clinical trial for its InFoods® diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. The clinical...
Biomerica Reports Fiscal 2021 Year End Results
IRVINE, Calif., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2021 financial results. During the year the Company made significant progress in its business by...
Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression
IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has issued a notice of allowance for Biomerica's first patent pertaining to a revolutionary new treatment option for patients suffering from...
Biomerica Launches New Website For Its EZ Detect™ Colorectal Disease Screening Test
IRVINE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced the launch of their new website for their EZ Detect™ Colon Disease Test product at https://ezdetect.com. The site features streamlined functionality and easy access to essential...
Source: https://incomestatements.info
Category: Stock Reports